While generally safe and well-tolerated, individuals with copper metabolism disorders, such as Wilsons disease, should avoid this treatment
not FDA-approved, and the FDA has specifically flagged it as a bulk drug substance not appropriate for compounding due to insufficient safety data
This can lead to contamination in medical settings and so using bacteriostatic water as part of the process helps to ensure that no biofilm forms on the peptides being reconstituted
What is well-established: Peripheral nerves can regenerate
Children under 12 years of age (lack of clinical data)
FDA will hold a two-day public meeting on July 2324, 2026 to discuss seven peptide bulk drug substances nominated for possible inclusion on the 503A Bulks List a wonky-sounding list that, in practice, helps determine what traditional compounding pharmacies can legally make when a patient needs something that isnt available as an FDA-approved drug